This course has expired. View available courses.
Respirology
COPD Evidence Briefs
COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians to be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply this knowledge to common cases seen in clinical practice.
DURATION
1.25 hr
PROFESSION
Physician
# OF CREDITS
1.5
ACCREDITATION
Mainpro+
EXPIRY DATE
2023-09-30
COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians to be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply this knowledge to common cases seen in clinical practice.
Faculty
John Axler, MD, LMCC, CCFP, FCFP
Andre Belanger, MD, CFPC
Jeff Habert, MD, CCFP, FCFP
Sol Stern, Bsc, MD, MCFP
Learning objectives
Upon completion of this continuing education program, participants will be better able to:
- Determine the role of inhaled corticosteroid therapy in patients with COPD
- Review the impact of COPD triple therapy (LAMA/LABA/ICS) on all-cause mortality
- Determine which patients with COPD could benefit from triple therapy (ICS/LAMA/LABA)
- Contrast the evidence supporting the role of single inhaler triple therapy (SITT) compared to multiple-inhaler triple therapy (MITT) in patients with COPD
- Contrast the current evidence supporting the use of dual bronchodilation (LAMA/LABA) versus triple therapy (ICS/LAMA/LABA) in a patient with a history of one acute exacerbation of (AECOPD) in the past year
- Discuss the risk-benefit considerations in using LAMA/LABA versus ICS/LAMA/LABA
- Review the evidence supporting the use of a single inhaler type in patients with COPD
- Review the potential benefits of switching patients with COPD from multiple inhaler types to a single inhaler type
- Review Canadian Thoracic Society COPD guideline recommendations for patients with significant symptom burden and low risk of AECOPD
- Discuss the evidence regarding the differences in response and safety between two dual bronchodilators (LAMA/LABA)
Accreditation
#
of credits: 1.5
Duration: 1.25 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
Learning Objectives
Upon completion of this continuing education program, participants will be better able to:
- Determine the role of inhaled corticosteroid therapy in patients with COPD
- Review the impact of COPD triple therapy (LAMA/LABA/ICS) on all-cause mortality
- Determine which patients with COPD could benefit from triple therapy (ICS/LAMA/LABA)
- Contrast the evidence supporting the role of single inhaler triple therapy (SITT) compared to multiple-inhaler triple therapy (MITT) in patients with COPD
- Contrast the current evidence supporting the use of dual bronchodilation (LAMA/LABA) versus triple therapy (ICS/LAMA/LABA) in a patient with a history of one acute exacerbation of (AECOPD) in the past year
- Discuss the risk-benefit considerations in using LAMA/LABA versus ICS/LAMA/LABA
- Review the evidence supporting the use of a single inhaler type in patients with COPD
- Review the potential benefits of switching patients with COPD from multiple inhaler types to a single inhaler type
- Review Canadian Thoracic Society COPD guideline recommendations for patients with significant symptom burden and low risk of AECOPD
- Discuss the evidence regarding the differences in response and safety between two dual bronchodilators (LAMA/LABA)
Mainpro+
ACCREDITATION
Respirology
Learning Category
COPD
Topic
0
Price
2023-09-30
Expiry Date
CAN-eng
Region/Language
Course Description
COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians to be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply this knowledge to common cases seen in clinical practice.
Faculty
John Axler, MD, LMCC, CCFP, FCFP
Andre Belanger, MD, CFPC
Jeff Habert, MD, CCFP, FCFP
Sol Stern, Bsc, MD, MCFP
Accreditation
This self-learning program has been certified by the College of Family Physicians of Canada for up to 1.5 Mainpro+ credit(s). Cert+ Program ID#: 196697
1.25 hr
Duration
0
Price
1.5
# of credits
